首批新冠肺炎重症患者今日接受瑞德西韦用药，可重点关注这4家公司！

格隆汇2020-02-06

格隆汇2月6日丨由美国吉利德公司开发的瑞德西韦2月5日在武汉正式启动临床试验，第一批病例入组工作就位，首批新型冠状病毒感染的肺炎重症患者今日接受用药。格隆汇综合梳理了与吉利德有关的上市公司，分别是博腾股份(300363.SZ)、永太科技(002326.SZ)、九洲药业(603456.SH)以及药明康德(603259.SH)(2359.HK)。博腾股份：吉利德为公司核心客户，为吉利德的瑞德西韦提供...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2009923779?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36","is_english":false,"pubTime":"2020-02-06 15:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2009923779","market":"sh","top_or_hot":-1,"title":"首批新冠肺炎重症患者今日接受瑞德西韦用药，可重点关注这4家公司！","media":"格隆汇","content":"<div>\n<p>格隆汇2月6日丨由美国吉利德公司开发的瑞德西韦2月5日在武汉正式启动临床试验，第一批病例入组工作就位，首批新型冠状病毒感染的肺炎重症患者今日接受用药。格隆汇综合梳理了与吉利德有关的上市公司，分别是博腾股份(300363.SZ)、永太科技(002326.SZ)、九洲药业(603456.SH)以及药明康德(603259.SH)(2359.HK)。 博腾股份：吉利德为公司核心客户，为吉利德的瑞德西韦提供...</p>\n\n<a href=\"http://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_5115326071_130e5ae7702000yc33.html\">网页链接</a>\n\n</div>\n","source":"sina_symbol","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>首批新冠肺炎重症患者今日接受瑞德西韦用药，可重点关注这4家公司！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n首批新冠肺炎重症患者今日接受瑞德西韦用药，可重点关注这4家公司！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-02-06 15:08 北京时间&nbsp;&nbsp;&nbsp;<a href=http://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_5115326071_130e5ae7702000yc33.html><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>格隆汇2月6日丨由美国吉利德公司开发的瑞德西韦2月5日在武汉正式启动临床试验，第一批病例入组工作就位，首批新型冠状病毒感染的肺炎重症患者今日接受用药。格隆汇综合梳理了与吉利德有关的上市公司，分别是博腾股份(300363.SZ)、永太科技(002326.SZ)、九洲药业(603456.SH)以及药明康德(603259.SH)(2359.HK)。 博腾股份：吉利德为公司核心客户，为吉利德的瑞德西韦提供...</p>\n\n<a href=\"http://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_5115326071_130e5ae7702000yc33.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"603456","symbol_name":"九洲药业","start_time":0,"source_url":"http://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_5115326071_130e5ae7702000yc33.html","article_id":"2009923779","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/480431b5715196c0e96044cc36788e36"],"rights":{"source":"sina_symbol","url":"http://cj.sina.cn/article/normal_detail?url=https://k.sina.cn/article_5115326071_130e5ae7702000yc33.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.title{#titleStyle#}a{#lv2TextColor#}.extra-info, .source{#sourceStyle#;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2009923779","pubTimestamp":1580972927,"columns":[],"sourceInfo":{"source_id":"sina_symbol","name":"新浪媒体新闻"},"weMediaInfo":null,"summary":"格隆汇2月6日丨由美国吉利德公司开发的瑞德西韦2月5日在武汉正式启动临床试验，第一批病例入组工作就位，首批新型冠状病毒感染的肺炎重症患者今日接受用药。格隆汇综合梳理了与吉利德有关的上市公司，分别是博腾","collect":0,"end_time":0,"defaultTopTitle":"sina.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"300363":"博腾股份","603259":"药明康德","603456":"九洲药业","002326":"永太科技"},"translate_title":"The first batch of critically ill patients in novel coronavirus pneumonia received Redsivir today, and we can focus on these four companies!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300363":0.6,"603259":0.6,"603456":0.6,"002326":0.6},"content_text":"格隆汇2月6日丨由美国吉利德公司开发的瑞德西韦2月5日在武汉正式启动临床试验，第一批病例入组工作就位，首批新型冠状病毒感染的肺炎重症患者今日接受用药。格隆汇综合梳理了与吉利德有关的上市公司，分别是博腾股份(300363.SZ)、永太科技(002326.SZ)、九洲药业(603456.SH)以及药明康德(603259.SH)(2359.HK)。 博腾股份：吉利德为公司核心客户，为吉利德的瑞德西韦提供CDMO服务；九洲药业：与吉利德于2011年开始合作，公司已为其提供多个品种的医药中间体CDMO 服务，近两年，吉利德公司的产品销售收入占公司营业收入不超过2%；永太科技：下游客户包括吉利德，在与吉利德接洽在研药物Remdesivir(瑞德西韦)的中间体采购；药明康德：与吉利德自2007年开始合作。2015年、2016年、2017年，吉利德进入了公司销售的前十大客户之列。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2009923779"}